Literature DB >> 33941610

Long Noncoding RNA CTD-2245E15.3 Promotes Anabolic Enzymes ACC1 and PC to Support Non-Small Cell Lung Cancer Growth.

Chen Wang1, Xiangfeng Meng2, Yu Zhou2, Jing Yu2, Qing Li2, Zhicong Liao3, Yuanyuan Gu2, Jiayi Han4, Shuo Linghu2, Zichen Jiao3, Tao Wang3, Chen-Yu Zhang1, Xi Chen1.   

Abstract

Long noncoding RNAs (lncRNA) have been shown to play critical regulatory roles in the onset and progression of human cancers. However, the functions of a large proportion of lncRNAs are still unexplored. Here we describe a novel lncRNA, CTD-2245E15.3, that promotes lung tumorigenesis by regulating the anabolic enzymes acetyl-CoA carboxylase 1 (ACC1, encoded by the ACACA gene) and pyruvate carboxylase (PC). Differentially expressed lncRNAs between non-small cell lung cancer (NSCLC) and paired adjacent nontumor tissues were identified by a microarray and validated using quantitative real-time polymerase chain reaction. CTD-2245E15.3 was significantly upregulated in NSCLC and was mainly located in the cytoplasm. Knockdown of CTD-2245E15.3 by specific antisense oligonucleotides suppressed cell growth in vitro and in vivo, largely due to cell-cycle arrest and induction of apoptosis. Overexpression of CTD-2245E15.3 in an orthotopic model of lung cancer led to a significant increase in total tumor burden. CTD-2245E15.3 exerted its oncogenic function by binding ACC1 and PC, which are key anabolic factors for biomolecule synthesis in rapidly proliferating tumor cells. Knockdown of CTD-2245E15.3 increased phosphorylation of ACC1 at an inhibitory site for enzymatic activity and promoted PC degradation via ubiquitination. Supplements of palmitate or oxaloacetate, products of ACC1 and PC, alleviated the suppression of cell growth caused by loss of CTD-2245E15.3. These findings reveal the important role of CTD-2245E15.3 as an oncogenic lncRNA in the anabolic process for tumor growth. SIGNIFICANCE: These findings demonstrate a novel lncRNA CTD-2245E15.3 that binds and positively regulates anabolic enzymes ACC1 and PC to promote tumor growth. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/13/3509/F1.large.jpg. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33941610     DOI: 10.1158/0008-5472.CAN-19-3806

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Long Noncoding RNAs and Circular RNAs in the Metabolic Reprogramming of Lung Cancer: Functions, Mechanisms, and Clinical Potential.

Authors:  Yuhao Zhou; Yuan Zhan; Weiling Jiang; Huiguo Liu; Shuang Wei
Journal:  Oxid Med Cell Longev       Date:  2022-06-15       Impact factor: 7.310

2.  LINC00092 Modulates Oxidative Stress and Glycolysis of Breast Cancer Cells via Pyruvate Carboxylase-Mediated AKT/mTOR Pathway.

Authors:  Wei Chen; Yushan Liu; Shaohong Kang; Xinying Lv; Wenfen Fu; Jie Zhang; Chuangui Song
Journal:  Oxid Med Cell Longev       Date:  2022-06-28       Impact factor: 7.310

3.  LCAT1 is an oncogenic LncRNA by stabilizing the IGF2BP2-CDC6 axis.

Authors:  Juze Yang; Xinyi Qian; Qiongzi Qiu; Lingling Xu; Meidie Pan; Jia Li; Jiayi Ren; Bingjian Lu; Ting Qiu; Enguo Chen; Kejing Ying; Honghe Zhang; Yan Lu; Pengyuan Liu
Journal:  Cell Death Dis       Date:  2022-10-18       Impact factor: 9.685

Review 4.  LncRNAs and CircRNAs in cancer.

Authors:  Xin Yin; Huiran Lin; Lei Lin; Lei Miao; Jing He; Zhenjian Zhuo
Journal:  MedComm (2020)       Date:  2022-05-12

Review 5.  Close interactions between lncRNAs, lipid metabolism and ferroptosis in cancer.

Authors:  Jingjing Huang; Jin Wang; Hua He; Zichen Huang; Sufang Wu; Chao Chen; Wenbing Liu; Li Xie; Yongguang Tao; Li Cong; Yiqun Jiang
Journal:  Int J Biol Sci       Date:  2021-10-25       Impact factor: 6.580

Review 6.  Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy.

Authors:  Leqiang Zhang; Ning Chang; Jia Liu; Zhuojun Liu; Yajin Wu; Linlin Sui; Wei Chen
Journal:  Front Oncol       Date:  2022-08-29       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.